evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

79 questions · 82 findings · 10 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 12 · 14.6%GRADE not reported 0 · 0%Very low 33 · 40.2%Low 19 · 23.2%Moderate 16 · 19.5%High 2 · 2.4%

Infliximab vs placebo

At least 50% decrease in HS Severity Index · participants with hidradenitis suppurativa

Infliximab showed no clear difference in at least 50% decrease in HS Severity Index compared with placebo (moderate certainty).

1 finding from 1 review

Infliximab vs placebo

Physician Global Assessment (Thongprasom score) · participants with hidradenitis suppurativa

Infliximab probably leads to higher physician global assessment compared with placebo (moderate certainty).

1 finding from 1 review

Infliximab 5 mg/kg vs infliximab 10 mg/kg

Withdrawals due to adverse events · Patients with active Crohn's disease

The review found no eligible studies for this question.

2 findings from 1 review

Infliximab 5 mg/kg vs infliximab 10 mg/kg

Clinical remission defined as absence of any draining fistulas at ≥ 2 consecutive visits, at a median 12 weeks · Patients with active Crohn's disease

It is very uncertain whether infliximab 5 mg/kg changes clinical remission defined as absence of any draining fistulas at ≥… compared with infliximab 10 mg/kg (very low certainty).

1 finding from 1 review

Infliximab 5 mg/kg vs infliximab 10 mg/kg

Clinical response defined as reduction of 50% in the number of draining fistula at ≥ 2 consecutive visits, at a median length of time of 12 weeks · Patients with active Crohn's disease

It is very uncertain whether infliximab 5 mg/kg changes clinical response defined as reduction of 50% in the number of… compared with infliximab 10 mg/kg (very low certainty).

1 finding from 1 review